Instrument Inactif

Autres langues Asahi Kasei Corporation Other OTC

Actions

AHKSY

US0434001006

Chimie diversifiée

Autres langues

01/10	Teijin Frontier, Asahi Kasei Advance Merge to Form TA Frontier
29/09	Asahi Kasei to Integrate Global Pharmaceutical Brand Under Asahi Kasei Therapeutics
17/09	Asahi Kasei : Statement on arrest of former employee
15/09	Asahi Kasei Bioprocess Unveils Vantij Su-Vfc Benchtop for Automated Single-Use Virus Filtration
15/09	Asahi Kasei Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing
15/09	Asahi Kasei : Introduces VANTIJ® SU-VFC Benchtop to Improve Efficiency and Consistency in Gene Therapy Manufacturing
14/09	Asahi Kasei Unit Starts Phase Two Study of Antifungal Cresemba for Pediatric Patients in Japan
14/09	Asahi Kasei : Begins Phase II Clinical Trial of isavuconazonium sulfate for Pediatric Patients in Japan
08/09	Asahi Kasei Microdevices’ CZ39 and CZ3K Current Sensors Featured in Microchip Technology’s Machine Learning-Based Arc Fault Detection Reference Design
08/09	Asahi Kasei : Microdevices’ CZ39 and CZ3K Current Sensors Featured in Microchip Technology’s Machine Learning-Based Arc Fault Detection Reference Design
01/09	Asahi Kasei : Veloxis Pharmaceuticals Doses First Patient in RENGEVITY-201 Phase 2 Trial of Pegrizeprument for the Prevention of Organ Rejection in Kidney Transplant Recipients
26/08	Asahi Kasei Unveils New Wet-Process Separator Coating Line in North Carolina, Advancing the Company?s 40-Year North American Battery Separator Strategy
26/08	Asahi Kasei Unveils New Wet-Process Separator Coating Line in North Carolina, Advancing the Company’s 40-Year North American Battery Separator Strategy
26/08	Asahi Kasei : Unveils New Wet-Process Separator Coating Line in North Carolina, Advancing the Company’s 40-Year North American Battery Separator Strategy
24/08	Asahi Kasei : Empaveli™ Approved in Japan for Additional Rare Kidney Disease Indications of C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis
24/08	Asahi Kasei : Contract Signed with JOGMEC for Design Work Related to Ship-Based Advanced CCS Project
20/08	Asahi Kasei's Capacity Expansion for Water Electrolysis and Chlor-Alkali Equipment in Kawasaki Awarded Regional Economic Incentives
20/08	Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries
20/08	Asahi Kasei Develops Novel Lithium Pre-Doping Technology For Silicon-Rich Lithium-Ion Batteries
20/08	Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries
20/08	Asahi Kasei : Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries
19/08	Asahi Kasei’s Capacity Expansion for Water Electrolysis and Chlor‑Alkali Equipment in Kawasaki Awarded Regional Economic Incentives
19/08	Asahi Kasei Expands Capacity For Water Electrolysis And Chlor-Alkali Equipment In Kawasaki
19/08	Asahi Kasei : Capacity Expansion for Water Electrolysis and Chlor‑Alkali Equipment in Kawasaki Awarded Regional Economic Incentives
18/08	Asahi Kasei : selected for continued inclusion in the ESG indices FTSE4Good Index Series, FTSE JPX Blossom Japan Index, and FTSE JPX Blossom Japan Sector Relative Index